Search

CMSC Abstracts View

Search Accepted Abstracts
Sending

Search Results

Year ID Type Category Title Authors
2018 RH22 Poster Rehabilitation Posters

A Complementary and Alternative Medicine (CAM) Intervention for Building a TeleHealth Platform for People with MS

Tracy Flemming Tracy, OTR/L, MSCS, MSSMC1, Emily Riser, MD2, James Rimmer, Ph D3, Mohan Thirumalai, PhD3, Tapan Mehta, PhD3, Hui-Ju Young, PhD3, Whitney Neal, MA4, Ritalinda Lee, PhD5 and Dorothy Pekmezi, PhD6, (1)Rehabilitation, Tanner Center for MS, Birmingham, AL, (2)Tanner Center and Foundation for Multiple Sclerosis, Birmingham, AL, (3)School of Health Professions, UAB/Lakeshore Foundation Collaborative, Birmingham, AL, (4)UAB/Lakeshore Foundation Collaborative, Birmingham, AL, (5)Claris Technical Services, Huntsville, AL, (6)School of Public Health, University of Alabama, Birmingham, Birmingham, AL

2018 RH23 Poster Rehabilitation Posters

Examining the Role of Physical Activity, Fitness, and Exercise for Managing Vascular Comorbidities in People with Multiple Sclerosis: A Scoping Review

Benjamin W. Ewanchuk, BSc, The University of Calgary, Calgary, AB, Canada, Marjan Gharagozloo, MSc, University of Sherbrooke, Sherbrooke, QC, Canada, Evelyn Peelen, PhD, CR-CHUM, Montreal, QC, Canada and Lara A. Pilutti, PhD, Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, ON, Canada

2018 RH24 Poster Rehabilitation Posters

The Energy Management Program in Support of Restoration and Renewal for Persons with MS (EMPIRe2): An Initial Evaluation

Natasha Hoover, OT (Candidate)1, Forwell Susan, PhD (OT), MA (OT), BSC (OT), FCAOT2 and Denise Kendrick, BA, MOT2,3, (1)Occupational Science and Occupational Therapy, University of British Columbia, British Columbia, BC, Canada, (2)Department of Occupational Science and Occupational Therapy, University of British Columbia, Vancouver, BC, Canada, (3)Vancouver Coastal Health, UBC MS/NMOSD Clinic, Vancouver, BC, Canada

2018 RH25 Poster Rehabilitation Posters

Dalfampridine May Enhance the Effects of Physical Therapy on Gait in People with Multiple Sclerosis

Prudence Plummer, Ph.D.1, Whitney W Huryta, DPT2, Jessica H Reynolds, DPT2, Silva Markovic-Plese, MD3 and Barbara Giesser, MD4, (1)Division of Physical Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC, (2)Allied Health Sciences, University of North Carolina, Chapel Hill, NC, (3)Department of Neurology, Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, (4)Neurology, UCLA, Los Angeles, CA

2018 RT01 Poster Relapse Therapy

A Case of Fulminant Recurrent Tumefactive Demyelinating Lesions

William A Kilgo, MD, Benjamin A Jones, MD and Khurram Bashir, MD, MPH, Neurology, University of Alabama at Birmingham, Birmingham, AL

2018 RT02 Poster Relapse Therapy

A Prospective Observational Registry of Repository Corticotropin Injection for the Treatment of Multiple Sclerosis Relapse: Baseline Characteristics and Interim Results

Bryan R Due, PhD, Clinical Sciences, Mallinckrodt ARD Inc, Bedminster, NJ, Patrice M Becker, MD, Science & Technology, Mallinckrodt ARD Inc, Bedminster, NJ and Patricia K Coyle, MD, Stony Brook University, Stony Brook, NY

2018 SC01 Poster Self-care

Best Practices for Encouraging Physical, Emotional and Nutritional Wellness in Patients with Multiple Sclerosis (MS)

Bryan Walker, PA-C1, Aliza Ben-Zacharia, DNP2, Amy Dix, PA-C3, Jong Mi Lee, MD4, Carrie Sammarco, DNP, FNP-C, MSCN5, Jollene Shirley, MSN, BSN, RN, CNP6 and Colleen Miller, RN, NP, DNS6, (1)Neurology, Duke University, Durham, NC, (2)The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, (3)Kansas City MS Center, Prairie Village, KS, (4)Stanford Healthcare, Stanford, CA, (5)MS Comprehensive Care Center, New York, NY, (6)Sanofi, Cambridge, MA

2018 SC02 Poster Self-care

MS Self[TM]: An Educational Mobile Application for Recording Multiple Sclerosis-Related Experiences and Symptoms

Natalie Rosado-Baron, _, Richard Muser, _, Michael Russo, _ and Holly Roberts, MD, Acorda Therapeutics, Inc, Ardsley, NY

2018 SC03 Poster Self-care

Attitudes Toward Vaccines in People with Multiple Sclerosis

Lien Nguyen, DO1, Kevin N Alschuler, PhD2, Annette Wundes, MD1 and Gloria von Geldern, MD3, (1)Neurology, University of Washington, Seattle, WA, (2)Rehabilitation Medicine, University of Washington School of Medicine, Seattle, WA, (3)University of Washington, Seattle, WA

2018 SC04 Poster Self-care

What MS Veterans Want to Know about MS: Subjects and Formats

L Hillman, DNP, MSCoE, VA PSHCS, Seattle, WA

2018 SX01 Poster Symptom Management

Pediatric Multiple Sclerosis: Current Perspectives

Elizabeth M Sikes, MS OTR/L1, Rob Motl, PhD1 and Jayne Ness, PhD2, (1)Department of Physical Therapy, UAB, Birmingham, AL, (2)Department of Pediatrics, UAB, Birmingham, AL

2018 SX02 Poster Symptom Management

Evaluation of a Spasticity Management Program for People with Multiple Sclerosis: Study Protocol

Cinda L Hugos, MS, PT, Neurology, Oregon Health & Science University, Portland, OR; Research, VA Portland Health Care System, Portland, OR and Michelle H Cameron, MD, PT, Neurology, Oregon Health and Science University, Portland, OR; Neurology, VA Portland Health Care System, Portland, OR

2018 SX03 Poster Symptom Management

Persistent Genital Arousal Disorder – a Case Study

Imogen Milner, BN, MSCN, Neurology OPD, Wellington Hospital, CCDHB, Wellington, New Zealand

2018 SX04 Poster Symptom Management

Piloting a Mobile Platform in Multiple Sclerosis Patients Taking Oral Disease-Modifying Therapies

Devin S. Mullin, BS1, Cindy Gonzalez, MPH1, Taylor J. Saraceno, BS1, Kelsey Rankin, BA2, Eyal Bartfeld, DMD, PhD3, Brian C. Healy, PhD1, Riley Bove, MD, MMSc2 and Tanuja Chitnis, MD1, (1)Partners Multiple Sclerosis Center, Brigham and Women’s Hospital, Boston, MA, (2)University of California San Francisco, Weill Institute for Neurosciences, San Francisco, CA, (3)Irody, Inc., Boston, MA

2018 SX05 Poster Symptom Management

Scrambler Therapy: Potential New Treatment for Central Neuropathic Pain?

Maureen A. Mealy, PhD(c), RN1,2, Sharon L. Kozachik, PhD, RN2, Lawrence Cook, MS, PhD3, Scott D. Newsome, DO1, Michael Levy, MD, PhD1 and Thomas J. Smith, MD4, (1)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (2)Acute and Chronic Care, Johns Hopkins University School of Nursing, Baltimore, MD, (3)Pediatrics, University of Utah, Salt Lake City, UT, (4)Oncology, Johns Hopkins University School of Medicine, Baltimore, MD

2018 SX06 Poster Symptom Management

Multiple Sclerosis and Use of Medical Cannabis- a Retrospective Review Evaluating Symptom Outcomes

Katelyn E McCormack, ANP-C, FNP-C and Amir C Mazhari, MD, Amherst, NY

2018 SX07 Poster Symptom Management

A Recurrent Case of Balo’s Concentric Sclerosis: Multiple Sclerosis Variant

Carrie Downey, DO, Neurology, University of South Florida, Riverview, FL and Charles Schutt, MD, Neurology, University of South Florida, Tampa, FL

2017 CC01 Platform/Oral Comprehensive Care in MS and Symptom Management

What Patients Expect from Their MS Nurse: Canadian Survey Results

Colleen Harris, MN, NP, MSCN, MSCS, University of Calgary MS Clinic, Hackensack, NJ, Bonnie Blain, RN, MSCN, Medical Specialty Clinic, Red Deer Regional Hospital Centre, Alberta Health Services, Red Deer, AB, Canada, Janet Brown, RN, MSCN, MS Clinic-Eastern Health, St. John’s, NF, Canada, Peggy Cook, RN, BN, Saint John Regional Hospital, Saint John, NB, Canada and Josee Poirier, BSs, MSCN, Hopital Notre-Dame, Montreal, QC, Canada

2017 CC02 Platform/Oral Comprehensive Care in MS and Symptom Management

Self-Reported Personal Impact of MS Wellness Programs

Debra I Frankel, MS OTR, Advocacy, Services and Research Department, National Multiple Sclerosis Society, NY, NY and Sara Anne Tompkins, Ph.D., Program Planning and Evaluation Consulting, Madipen, LLC, Fort Collins, CO

2017 CC03 Platform/Oral Comprehensive Care in MS and Symptom Management

Shared Decision Making: Connecting Clinicians and Patients to Improve Patient Outcomes

Elaine Rudell, CHCP1, Patty Peterson, CHCP1, Sandeep Pulim, MD1, Andrea L Griffin, none2 and James D Bowen, MD3, (1)@Point of Care, Livingston, NJ, (2)Multiple Sclerosis Association of America, Cherry Hill, NJ, (3)Swedish Medical Center, Seattle, WA

2017 CC04 Platform/Oral Comprehensive Care in MS and Symptom Management

Patient Input into Multiple Sclerosis Quality and Outcome Measures

Jeffrey B English, MD1, Lauren Alexander, Pre-Med Student2 and Nancy Flockhart, BS, CCRC2, (1)Multiple Sclerosis Center of Atlanta, Atlanta, GA, (2)Research, Multiple Sclerosis Center of Atlanta, Atlanta, GA

2017 CC05 Platform/Oral Comprehensive Care in MS and Symptom Management

Factors Associated with Pediatric Onset Multiple Sclerosis Slowed Gait, Does Mood Matter?

Hong Li, MS, Quantitative health Sciences, Cleveland Clinic, Cleveland, OH, Carolyn Bauer, BS, Biology, The Miami University, Oxford, OH and Mary R Rensel, MD, The Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH

2017 CC06 Platform/Oral Comprehensive Care in MS and Symptom Management

Goals of Care in People Living with Advanced Multiple Sclerosis

Rachael Stacom, ANP, MSCN, Care Management, Independence Care System, New York, NY

2017 CG01 Platform/Oral Psychosocial: Cognition, Depression

Goal Attainment in a MS Cognitive Intervention Study

Ana T Todd, PhD RN1, Heather Becker, PhD, Research Scientist2, Alexa Stuifbergen, PhD, RN, FAAN, Dean2, Wenshui Zhang, BSN3 and Vicki Kullberg, MA3, (1)School of Nursing, University of Texas at Austin, Austin, TX, (2)School of Nursing, The University of Texas at Austin, Austin, TX, (3)School of Nursing, University of Texas Nurs, Austin, TX

2017 CG02 Platform/Oral Psychosocial: Cognition, Depression

The Mediating Role of Cognitive Fatigue on the Relationship Between Anxiety and Illness Intrusiveness in Multiple Sclerosis Patients

Caroline Altaras, B.A.1, Nicholas A Vissicchio, B.A.1, Shonna Schneider, B.A.2, Shaina Shagalow, B.A.2, Amanda A Parker, B.S.2, Jennifer Miller, B.A.2 and Frederick W Foley, Ph.D.3, (1)Yeshiva University Ferkauf Graduate School of Psychology, Bronx, NY, (2)Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, (3)School of Psychology, Yeshiva University, New York, NY

2017 CG03 Platform/Oral Psychosocial: Cognition, Depression

The Relationship Between Social Cognition Impairments and Fatigue, Depression and Anxiety in Individuals with Multiple Sclerosis

Helen Genova, PhD1, Jean Lengenfelder, Ph.D.2, Chris Bober, BA1, John DeLuca, Ph.D.3 and Nancy D Chiaravalloti, PhD1, (1)Neuropsychology and Neuroscience, Kessler Foundation, East Hanover, NJ, (2)Traumatic Brain Injury, Kessler Foundation, East Hanover, NJ, (3)Neuropsychology and Neuroscience, Kessler Foundation, West Orange, NJ

2017 CG04 Platform/Oral Psychosocial: Cognition, Depression

Shifting to the Positive: Findings from the “Resilience Questionnaire in MS”

Karen VL Turpin, PhD Candidate, MSc, BScN, School of Public Health, University of Alberta, Edmonton, AB, Canada, Linda J Carroll, PhD, Public Health Sciences, University of Alberta, Edmonton, AB, Canada, Penelope Smyth, MD, FRCPC, Division of Neurology, Department of Medicine, University of Alberta, Edmonton, AB, Canada and Ruth Ann Marrie, MD, PhD, University of Manitoba, Winnipeg, MB, Canada

2017 CG05 Platform/Oral Psychosocial: Cognition, Depression

The Contribution of Stigma on Depression Symptoms and Depression Status Among Individuals Living with Multiple Sclerosis

Margaret H Cadden, M.S., Peter A Arnett, Ph.D. and Jonathan E Cook, Ph.D., Department of Psychology, Pennsylvania State University, State College, PA

2017 CG06 Platform/Oral Psychosocial: Cognition, Depression

The Impact of Natalizumab on Health-Related Quality of Life in Patients with Secondary-Progressive Multiple Sclerosis

Mark S Freedman, MD1, Douglas Jeffery, MD, PhD2,3, Aaron Miller, MD4, Eva Havrdova, MD, PhD5, Finn Sellebjerg, MD, PhD, DMSci6, Hans-Peter Hartung, MD7, Ih Chang, PhD8, Sarah Naoshy, MPH8 and Nolan Campbell, PhD8, (1)1University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON, Canada, (2)Cornerstone Healthcare, High Point, NC, (3)Piedmont HealthCare, Mooresville, NC, (4)Icahn School of Medicine at Mount Sinai, New York, NY, (5)First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic, (6)Danish Multiple Sclerosis Center, Ringshospitalet, University of Copenhagen, Copenhagen, Denmark, (7)Heinrich Heine University, Dusseldorf, Germany, (8)Biogen, Cambridge, MA

2017 CG07 Platform/Oral Psychosocial: Cognition, Depression

Mindfulness Training Vs. Adaptive Cognitive Training: Impact on Emotion Dysregulation and Cognitive Functioning

Ruchika S. Prakash, Ph.D.1, Brittney Schirda, MA1 and Hyunkyu Lee, PhD2, (1)Department of Psychology, The Ohio State University, Columbus, OH, (2)Posit Science, San Francisco, CA

2017 DX01 Platform/Oral Disease Management, Imaging and Therapeutics

Rapid and Robust B Cell Depletion in Preliminary Results of a Phase 2 Study of Ublituximab, Novel Glycoengineered Anti-CD20 Mab, in RMS Patients

Amy Lovett-Racke, PhD1, Yue Liu, MS1, Michael K Racke, MD2, Sibyl Wray, MD3, Richard Shubin, MD4, Cary L Twyman, MD5, Wendy Su, PhD6, James Eubanks, PhD6 and Edward J. Fox, MD, PhD7, (1)Microbial Infection and Immunity, Ohio State University Medical Center, Columbus, OH, (2)Wexner Medical Center, Ohio State University, Columbus, OH, (3)Hope Neurology Multiple Sclerosis Center, Knoxville, TN, (4)SC3 Research Group, Inc, Pasadena, CA, (5)Associates in Neurology PSC, Lexington, KY, USA, Lexington, KY, (6)Autoimmune, TG Therapeutics, New York, NY, (7)Central Texas Neurology Consultants, Round Rock, TX

2017 DX02 Platform/Oral Disease Management, Imaging and Therapeutics

Durable Efficacy of Alemtuzumab on Clinical and MRI Outcomes over 6 Years in Care-MS II Patients with Active RRMS with Relapse Between Courses 1 and 2

Barry A Singer, MD1, Simon Broadley, MD2, Angel Chinea, MD3, Mark S Freedman, MD4, Guillermo Izquierdo, MD5, Jan Lycke, MD6, Basil Sharrack, MD, PhD7, Brian Steingo, MD8, Heinz Wiendl, MD9, Sibyl Wray, MD10, David H Margolin, MD, PhD11, Sourav Santra, PhD12, Karthinathan Thangavelu, PhD11, Aaron Boster, MD13 and on behalf of the CARE-MS II and CAMMS03409 Investigators, n/a14, (1)MS Center for Innovations in Care, Missouri Baptist Medical Center, St Louis, MO, (2)School of Medicine, Gold Coast Campus, Griffith University, Gold Coast, Australia, (3)San Juan Multiple Sclerosis Center, San Juan, PR, (4)University of Ottawa and the Ottawa Hospital Research Institute, Ottowa, ON, Canada, (5)Virgen Macarena University Hospital, Seville, Spain, (6)University of Gothenburg, Gothenburg, Sweden, (7)Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, (8)Fort Lauderdale Multiple Sclerosis Center, Fort Lauderdale, FL, (9)University of Munster, Munster, Germany, (10)Hope Neurology Multiple Sclerosis Center, Knoxville, TN, (11)Sanofi Genzyme, Cambridge, MA, (12)Cytel, Cambridge, MA, (13)Ohio State University, Columbus, OH, (14)MA

2017 DX03 Platform/Oral Disease Management, Imaging and Therapeutics

When Should Disease-Modifying Treatments be Discontinued in Patients with Multiple Sclerosis: An Evidence-Based Review with Expert Recommendations

Devyn Parsons, BSc1, Virginia Devonshire, MD2, Robert Carruthers, MD2, Lorne Kastrukoff, MD2 and Anthony Traboulsee, MD1, (1)University of British Columbia, Vancouver, BC, Canada, (2)Neurology, University of British Columbia, Vancouver, BC, Canada

2017 DX04 Platform/Oral Disease Management, Imaging and Therapeutics

Benefits of Cladribine Tablets in Patients with Multiple Sclerosis Free from Clinical and Radiological Indicators of Disease Activity in the CLARITY EXTENSION Study

Gavin Giovannoni, MD1, Giancarlo Comi, MD2, Stuart Cook, MD3, Peter Rieckmann, MD4, Kottil Rammohan, MD5, Per Soelberg-Sorensen, MD6, Patrick Vermersch, MD7, Abidemi Adeniji, PhD8 and Fernando Dangond, MD8, (1)Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, United Kingdom, (2)University Vita-Salute San Raffaele, Milan, Italy, (3)Rutgers, The State University of New Jersey, Newark, NJ, (4)Akademisches Krankenhaus Sozialstiftung Bamberg, Bamberg, Germany, (5)Ohio State University Hospital, Columbus, OH, (6)Copenhagen University Hospital, Copenhagen, Denmark, (7)Univ. Lille, CHU Lille, LIRIC – INSERM U995, Lille, France, (8)EMD Serono, Inc., Billerica, MA

2017 DX05 Platform/Oral Disease Management, Imaging and Therapeutics

Efficacy and Safety of Ozanimod in the Blinded Extension (120 weeks) of RADIANCE, a Phase 2 Trial in Relapsing Multiple Sclerosis

Giancarlo Comi, MD1, Douglas L Arnold, MD2, Amit Bar-Or, MD2, Krzysztof Selmaj, MD, PhD3, Lawrence Steinman, MD4, Eva Havrdova, MD5, Bruce AC Cree, MD6, Hans-Peter Hartung, MD7, Ludwig Kappos, MD8, Brett E Skolnick, PhD9 and Jeffrey A Cohen, MD10, (1)Vita-Salute San Raffaele University, Milan, Italy, (2)Montreal Neurological Institute and Hospital McGill University, Montreal, QC, Canada, (3)Medical Academy of Lodz, Lodz, Poland, (4)Stanford University School of Medicine, Stanford, CA, (5)Charles University, Prague, Czech Republic, (6)Multiple Sclerosis Center, San Francisco, CA, (7)Heinrich-Heine-University Dusseldorf, Dusseldorf, Germany, (8)University of Basel, Basel, Switzerland, (9)Receptos Services LLC, San Diego, CA, (10)Mellen Center U-10 Cleveland Clinic, Cleveland, OH

2017 DX06 Platform/Oral Disease Management, Imaging and Therapeutics

Use of Rituximab Therapy in Improving Radiologic Evidence of Disease in Patients with Multiple Sclerosis

Mary Ann Picone, MD1, Laura Schiraldi, MS2, Fred Foley, PhD1 and Jeffrey Portnoy, PhD Candidate1, (1)Holy Name Medical Center, Teaneck, NJ, (2)Touro College of Osteopathic Medicine, New York, NY

2017 DX07 Platform/Oral Disease Management, Imaging and Therapeutics

Preliminary Results of the OPERA I and OPERA II Open-Label Extension Study

Robert T Naismith, MD1, Mark Cascione, MD2, Luigi ME Grimaldi, MD3, Stephen L Hauser, MD4, Ludwig Kappos, MD5, Xavier Montalban, MD, PhD6, Jerry Wolinsky, MD7, Peter Chin, MD8, Hideki Garren, PhD, MD8, Laura Julian, PhD8, Fabian Model, PhD9 and David Honeycutt, MD10, (1)Washington University School of Medicine, St. Louis, MO, (2)Axiom Clinical Research of Florida, Tampa, FL, (3)Fondazione Istituto – G. Giglio, Cefalu, PA, Italy, (4)University of California, San Francisco, San Francisco, CA, (5)University Hospital Basel, University of Basel, Basel, Switzerland, (6)Vall d’Hebron University Hospital, Barcelona, Spain, (7)McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, (8)Genentech Inc., South San Francisco, CA, (9)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (10)Neurology Associates P.A., Multiple Sclerosis Center of Greater Orlando, Maitland, FL

2017 RH01 Platform/Oral Rehabilitation Interventions

Dynamic Stability during Gait Is Altered in Persons with Multiple Sclerosis Who Have a Falls History Compared to Non-Fallers and Healthy Controls

Jessie Huisinga, PhD1, Alexander Peebles, MS2, Adam Bruetsch, MS1 and Sharon G Lynch, MD3, (1)Landon Center on Aging, University of Kansas Medical Center, Kansas City, KS, (2)Bioengineering Graduate Program, University of Kansas, Lawrence, KS, (3)Neurology, University of Kansas Medical Center, Kansas City, KS

2017 RH02 Platform/Oral Rehabilitation Interventions

The Relationship Between Variability of the Center of Mass and Base of Support Is Altered during Gait in Persons with Multiple Sclerosis

Jordan J Craig, MS1, Adam Bruetsch, MS2, Sharon G Lynch, MD3 and Jessie Huisinga, PhD2, (1)Bioengineering, University of Kansas Medical Center, Kansas City, KS, (2)Landon Center on Aging, University of Kansas Medical Center, Kansas City, KS, (3)Neurology, University of Kansas Medical Center, Kansas City, KS

2017 RH03 Platform/Oral Rehabilitation Interventions

Persons with Multiple Sclerosis Increase Their Dynamic Margin of Stability during Gait

Alexander Peebles, MS1, Adam Bruetsch, MS2, Sharon G Lynch, MD3 and Jessie Huisinga, PhD2, (1)Bioengineering Graduate Program, University of Kansas, Lawrence, KS, (2)Landon Center on Aging, University of Kansas Medical Center, Kansas City, KS, (3)Neurology, University of Kansas Medical Center, Kansas City, KS